Introduction
Percutaneous coronary intervention (PCI) technique has dramatically improved within the past 40 years to become the most widely used approach for myocardial revascularization. Constant innovations in catheters, wires, and stent technology have led to safer and more successful procedures, especially in elective setting. 1 Acute stent thrombosis [Type 4b myocardial infarction (MI)], new plaque rupture leading to acute coronary thrombotic occlusion (Type 1 MI), stroke or death remain serious, and rare PCI-related complications. 2 In contrast, periprocedural MI (Type 4a MI) and myocardial injury are much more frequent and usually considered as benign. [3] [4] [5] [6] [7] In 2012, the third universal definition of MI 8 was the first to provide a clinically oriented definition of both Type 4a MI and myocardial injury. Biochemical myocardial injury defined as an isolated rise in cardiac biomarkers was differentiated from a periprocedural proven ischaemia-related Type 4a MI. Myocardial injury was defined as an only rise of cardiac biomarkers above five-fold the upper limit. It has to be noted that this definition was revisited within the crucial time of generalization of high-sensitivity troponin in PCI centres but was not built specifically for their use. 9, 10 In 2013, an expert consensus document issued from the Society for Cardiac Angiography and Interventions (SCAI) proposed a definition with a higher biomarker threshold compared with the 2012 definition. 11 The rates of periprocedural MI and myocardial injury in elective complex PCI are not well known with these new definitions. More importantly their prognostic value is debated and often considered as simple biochemical events.
In this study, we describe precisely the incidence, risk factors, and prognostic impact of periprocedural MI and myocardial injury in contemporary elective PCI performed in stable patients.
Methods

Study design and population
In this prospective observational study, consecutive elective PCI performed between the 1 January 2014 and the 31 December 2015 at the Institute of Cardiology of Pitié-Salpêtrière hospital were analysed. Eligible patients were men and women with a negative high-sensitivity troponin T on admission and another measurement within 48 h after PCI. Patients with acute coronary syndrome or elevated high-sensitivity troponin T level at admission were excluded. The standard antithrombotic treatment during PCI was aspirin and parenteral anticoagulation with intravenous 0.5 mg/kg enoxaparin. Patients without P2Y 12 inhibitor at admission were treated once the coronary anatomy was known and the percutaneous revascularization indication confirmed; the P2Y 12 inhibitor was chosen by the interventional cardiologist. Stable patients already on ticagrelor or prasugrel (because of a prior acute coronary syndrome) were also included.
Biomarkers
The assay used in our centre measure troponin T with high-sensitivity using the immuno-analysis ECL-sandwich by Roche. The upper limit of the normal of high-sensitivity troponin T is defined as the 99th percentile value obtained in a healthy population with cardiovascular risk <10% and corresponds to a value below 14 ng/L. High-sensitivity troponin T measurements were performed before PCI on admission in the department and every morning after the PCI until discharge. According to the third universal definition of MI, the troponin threshold to consider a periprocedural MI or a myocardial injury was 70 ng/L within 48 h after PCI.
Baseline and data collection
We prospectively collected all patient baseline characteristics and procedural aspects including medications during hospitalization up to 30-day and 1-year after discharge. All coronary angiograms were reviewed independently at our institutional core lab. Flow limiting complications such as coronary dissection, loss of a side branch, slow-flow, thrombus, or distal embolization were adjudicated. Prolonged chest pain and electrocardiogram modifications criteria were collected through medical and procedural reports and nurse observation notes during and after the PCI procedure. High-risk features for PCI were collected including age >75 years, glomerular filtration rate below 60 mL/min, diabetes mellitus, obesity, history of acute coronary syndrome in the past 12 months, left ventricular ejection fraction <40%, multi-vessel disease, multiple stenting/ stent (two or more stents), stent length > _30 mm, left main stenting, stenting of venous, or arterial coronary graft. PCI failure was defined by the inability to inflate a balloon. Concomitant treatments were also recorded, with a particular attention to pre-PCI and post-PCI prescription of antiplatelet therapy. 
Endpoints and follow-up
Results
Characteristics of the patients
A total of 3416 PCI were performed during the inclusion time period of which 1666 (48.7%) were performed in an elective setting with a normal high-sensitivity troponin level at admission. Among the 1666 patients admitted for elective PCI, high-sensitivity troponin was available in 1390 patients after PCI ( Figure 1) . The baseline characteristics of our cohort are described in Table 1 showing an all comer population including PCI for chronic total occlusion (6.6%) and for allograft vasculopathy in heart transplantation patients (4.2%). non-invasive test. The vast majority of the cohort (90.2%) had at least one high-risk feature for PCI and half (49.7%) displayed three or more of these high-risk features. The description of the coronary lesions, PCI procedures and discharge details such as treatment and hospital stay are described in Table 2 .
Primary composite endpoint
The primary endpoint occurred in 28.7% of the patients. It consisted of 0.14% of Type 4b MI, 7.0% of periprocedural MI, and 21.6% of periprocedural myocardial injury ( Figure 2 ). In comparison, the rate of periprocedural MI using the second universal definition and the SCAI definition was respectively 43.8% (n = 609) and 1.5% (n = 21). The level of high-sensitivity troponin release according to the type of PCIrelated event is described in Figure 3 . The details of clinical and procedural proofs of myocardial ischaemia in periprocedural MI are displayed in Table 3 .
Secondary endpoints and follow-up at 30 days and 1 year
Patients who suffered from a periprocedural MI or myocardial injury had longer hospitalization stay (1.9 vs. 1.1 day, P < 0.001). More importantly, they had a five-fold increase in cardiovascular events at 30 days [5.5% vs. 1.2%, hazard ratio (HR) 4.9, 95% confidence interval (CI) 2.3-10.5; P < 0.0001], mainly driven by ischaemic events (3.5% vs. 0.6%, HR 5.9, 95% CI 2.9-20; P <0.0001) compared with patients free of periprocedural MI or myocardial injury ( Figure 4A and Table 4 ). This increase in the risk of cardiovascular events at 30 days remained significant after adjustment (adjHR = 3.8, 95% CI 1.9-6.9; P < 0.001). Taken separately, periprocedural MI and myocardial injury both had a significant impact on cardiovascular events at 30 days (HR 6.6, 95% CI 7.2-120.1; P < 0.0001 for periprocedural MI and HR 4.4, 95% CI 2.8-15.5; P < 0.0001 for periprocedural myocardial injury). At 1-year, the risk of ischaemic events after discharge was significantly increased in patients with periprocedural MI and myocardial injury (10.5% vs. 6 .6%, adjHR = 1.7, 95% CI 1.1-2.6; P = 0.01) ( Figure 4B ). Periprocedural MI had a significant impact on events at 1 year, while myocardial injury did not (HR 1.9, 95% CI 1.3-5.5; P < 0.001 and HR 1.7 95% CI 0.9-2.3; P = 0.056, respectively) ( Table 5) . Interestingly, patients with a post-PCI troponin increase below 70 ng/L without ischaemic proofs had a similar rate of events than patients with a post-PCI troponin below 14 ng/L (1.3% vs. 0.8%, P = 0.4 at 30 days and 6.7% vs. 6 .6%, P = 0.8 at 1 year, respectively).When using the SCAI definition of periprocedural MI, the increase in the risk of ischaemic events at 1 year was even higher (23.7% vs. 7 .7%, P <0.001 HR =3.9 95% CI 3.0-92.1). However, although the SCAI definition was more specific to identify highest risk patients for ischaemic event at 30 days and 1 year (97% and 98.6%, respectively), this was at the expense of an important drop in sensitivity (5.5% and 3.7%). We found that the best post-PCI troponin thresholds to predict cardiovascular adverse events at 30 days and 1 year were, respectively, 85.5 ng/L and 97.7 ng/L. Sensitivity and specificity of the third universal definition of MI and the SCAI definition are provided in the Supplementary Material online.
Risk factors for periprocedural myocardial infarction and myocardial injury
Patients with periprocedural MI and myocardial injury were older, had more frequently impaired renal function, multi-vessel disease as well as multiple stenting (38.6%). PCI-related high-risk features were more common in patients with periprocedural complications (3.0 ± 1.6 vs. 2.3 ± 1; P < 0.0001) including higher rate of left main disease, multi-vessel disease, multiple stenting, and longer stent implantation compared with patients without complications. Of note, there were no differences related to gender in the rate of periprocedural Theses periprocedural events did impact the long-term prognosis of the patients with an increase of ischaemic events at 1 year. Of importance, most of the patients who developed one of these events carried high-risk features defining complex PCI, with significant predictable factors that could be anticipated before or during PCI. Interestingly, off-label use of potent P2Y 12 inhibitors (prasugrel and ticagrelor) was frequent and was motivated either in the pre-PCI setting by the presence of high-risk features or in the post-PCI setting if a periprocedural MI or myocardial injury occurred. Definitions of periprocedural MI remain a subject of controversy especially now that high-sensitivity troponin is used in routine practice. This was well illustrated in this study with rates of periprocedural MI ranging from 7% to 40% according to the definition used. In this study, the threshold of troponin level corresponding to the third universal definition of 2012 was the best to predict adverse cardiovascular events at short-and long-term. To our knowledge, the present study is the first to show a negative impact of periprocedural MI and myocardial injury in an elective setting, on ischaemic events and rehospitalization at 30 days and on ischaemic events at 1 year. 4, 9, 14 In a recent study, Ndrepepa et al. 4 found that increased mortality after elective PCI was mainly associated with the presence of a positive biomarker at baseline, independently from the post-PCI troponin level. In the present study, patients with positive high sensitivity troponin level (>14 ng/L) were excluded to focus on stable patients and directly measure the impact of periprocedural events. Myocardial injury has already been associated with an increased short-and long-term mortality in non-cardiac critically ill 15 viable myocardium is proportional to the extent of troponin elevation provide supportive arguments for the impact of myocardial injury, although probably driven by the highest increase in troponin release post-PCI. 18, 19 Whether periprocedural MI and myocardial injury are causal factors of short-or long-term clinical outcomes or just a reflection of a more severe coronary disease is unknown so far and warrant further clinical investigation. Myocardial injury can be related to silent myocardial cell necrosis corresponding to microvascular perfusion impairment, thrombus micro-embolization, or slow-flow that could not be captured. [20] [21] [22] Our findings support that myocardial injury and Type 4 MI should be clearly assessed when reporting the rate of periprocedural events of PCI. This is especially true for clinical trials evaluating the efficacy of a new drugs or new devices targeting ischaemic events during PCI. This has been the case for trials targeting the release of troponin in acute coronary syndrome, either by inhibiting inflammatory pathways 23 or by improving platelet inhibition through higher level of P2Y 12 receptor blockade. [24] [25] [26] [27] In our population, the majority of patients cumulated both clinical and angiographic high-risk factors. Percutaneous coronary intervention for these patients is often considered as 'complex' or at risk of periprocedural complications. 28 Although the definition of complex PCI is not standardized, we found that procedural characteristics such as left main stenting, multiple, and/or long stenting but also advanced age and renal impairment were independently associated with periprocedural complications, which is consistent with a previous study. 14 Such patients could therefore be candidates for more potent P2Y 12 inhibitors than the standard of care clopidogrel. In this study, prasugrel and ticagrelor were prescribed in almost one out of four patients in this study. The off-label use of prasugrel and ticagrelor was mainly observed for complex procedures including left main PCI or multiple stenting, but also following a periprocedural complication.
This reflects the willingness to avoid periprocedural complications and further ischaemic events, and was integrated to the latest guidelines on DAPT for high-risk patients. 29, 30 Evidence on the subject should be provided by the randomized ALPHEUS trial (Assessment of Loading with the P2Y 12 inhibitor Ticagrelor or clopidogrel to Halt ischaemic Events in patients Undergoing elective coronary Stenting, NCT02617290).This trial is currently recruiting patients with highrisk features for PCI in an elective setting and evaluate the potential 
Limitations
Finally, we acknowledge several limitations to this study. First, this is a cohort study with inherent biases. While prolonged chest pain and electrocardiogram changes could have been underreported, all angiographic films were reviewed in a core lab with blinded adjudication to identify all the periprocedural MI. Second, a minority of patients were excluded because they were transferred back to their reference centre that did not provide a troponin measurement. Third, we expected a low rate of hard clinical events in this clinical setting and therefore we chose a broader composite endpoint at 30 days reflecting the different causes of re-hospitalization after a PCI procedure, which is relevant in daily clinical practice. However, for the long-term prognosis at 1 year, we restricted our analysis to ischaemic events only. 
Supplementary material
Supplementary material is available at European Heart Journal online.
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